Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological Basis of Durable Antibody Responses to 9-valent HPV Vaccination
NCT05031078Phase 4Completed
- Sponsor
- Emory University
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (3 arms), sponsored by Emory University. Primary endpoint: Number of Participants With a Minimum Four-fold Rise in Post-vaccination HPV-16 and HPV-18 Neutralizing Antibody Titers at Day 210. Started Dec 2021; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05031078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031078.